Market Place
Sourcing Support
TCBP Announces Transition from Nasdaq to OTC Markets
21 Mar 2025 //
PR NEWSWIRE
TCBP Announces Intent to Acquire Ophthalmic Pharma Co.
05 Mar 2025 //
PR NEWSWIRE
TCBP CEO Bryan Kobel Joins Cancer Progress Panel At European Forum
20 Feb 2025 //
PR NEWSWIRE
TCBP Completes Cohort A In ACHIEVE Clinical Trial
13 Feb 2025 //
PR NEWSWIRE
TCBP Completes Initial Cohort B Dosing In ACHIEVE Trial
10 Feb 2025 //
PR NEWSWIRE
TCBP to Implement ADS Ratio Change
05 Feb 2025 //
PR NEWSWIRE
TCBP Announces H5N1 Proof of Concept Studies Intention
15 Jan 2025 //
PR NEWSWIRE
TCBP to Present at Sequire Investor Summit 2025
13 Jan 2025 //
PR NEWSWIRE
TCBP Trading Continues Unabated on Nasdaq Stock Exchange
06 Jan 2025 //
PR NEWSWIRE
TCBP Issues 25% Stock Dividend
06 Jan 2025 //
PR NEWSWIRE
TCBP Issues 25% Stock Dividend
30 Dec 2024 //
PR NEWSWIRE
TCBP Advances ACHIEVE Phase 2b Trial with Final Dosing
20 Dec 2024 //
PR NEWSWIRE
CareDx Partners With TC BioPharm On ACHIEVE Trial Monitoring
11 Dec 2024 //
BUSINESSWIRE
TCBP Partners With CareDx To Aid Cell Therapy Pharmacokinetic Study
11 Dec 2024 //
PR NEWSWIRE
TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial
04 Dec 2024 //
PR NEWSWIRE
TCBP Provides Shareholder Update on Recent Milestone Achievements
30 Oct 2024 //
PR NEWSWIRE
TCBP Responds to False Social Media Claim
25 Oct 2024 //
PR NEWSWIRE
TCBP Enters Research Collaboration For Mpox Therapeutic
22 Oct 2024 //
PR NEWSWIRE
TCBP Announces Site Opening of Guys and St. Thomas Hospital
25 Sep 2024 //
PR NEWSWIRE
TCBP to Present at the 2024 ThinkEquity Conference in NYC
24 Sep 2024 //
PR NEWSWIRE
TCBP Reports First Patient Completion In ACHIEVE Trial
20 Sep 2024 //
PR NEWSWIRE
TCBP Announces Milestone In ACHIEVE Clinical Trial
12 Sep 2024 //
PR NEWSWIRE
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
06 Sep 2024 //
PR NEWSWIRE
TCBP Announces Dosing of 5 New Patients in ACHIEVE
03 Sep 2024 //
PR NEWSWIRE
TC BioPharm Granted European Patent For Modified Gamma Delta Cells
28 Aug 2024 //
PR NEWSWIRE
TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering
28 Aug 2024 //
PR NEWSWIRE
TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b)
15 Aug 2024 //
PR NEWSWIRE
TC BioPharm Announces Closing of $2.0 Million Public Offering
15 Aug 2024 //
PR NEWSWIRE
TC BioPharm Announces Pricing of $2.0 Registered Direct Offering
13 Aug 2024 //
PR NEWSWIRE
TCBP Announces Launch of Compassionate Use Program for TCB008
15 May 2024 //
PR NEWSWIRE
TC BioPharm announces second letter of intent for CAR-T therapies
06 May 2024 //
PR NEWSWIRE
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
06 May 2024 //
PR NEWSWIRE
TCBP Announces Execution for Acquisition of NK Platform Technologies
04 Apr 2024 //
PR NEWSWIRE
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process
02 Apr 2024 //
PR NEWSWIRE
TCBP Adjourns General Meeting Until a Later Date
19 Mar 2024 //
PR NEWSWIRE
TCBP Announces Exercise of Series D Warrants For Cash
18 Mar 2024 //
PR NEWSWIRE
TC BioPharm Chief Executive Officer, Bryan Kobel Featured on `The Big Biz Show`
29 Jan 2024 //
PR NEWSWIRE
TC BioPharm to Present at the Sequire Investor Summit
18 Jan 2024 //
PR NEWSWIRE
TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement
04 Jan 2024 //
PR NEWSWIRE
TC BioPharm Announces Additional Cost Reduction Steps
03 Jan 2024 //
PR NEWSWIRE
TC BioPharm Announces Closing of $3.5 Million Public Offering
22 Dec 2023 //
PR NEWSWIRE
TC BioPharm Announces Pricing of $3.5 Million Public Offering
19 Dec 2023 //
PR NEWSWIRE
TC BioPharm Announces Formation of Commercial Development Division
18 Dec 2023 //
PR NEWSWIRE
TC BioPharm Announces Plan to Implement ADS Ratio Change
13 Dec 2023 //
PR NEWSWIRE
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008
27 Nov 2023 //
PR NEWSWIRE
TC BioPharm Announces Successful Completion of Positive DSMB Results
14 Nov 2023 //
PR NEWSWIRE
TC BioPharm Announces Reduces Overhead with Selection of Single Global CRO
02 Nov 2023 //
PR NEWSWIRE
TC BioPharm Taps Excellos as CDMO
25 Oct 2023 //
CONTRACT PHARMA
TC Bio Announces Submission of IND for Treatment of Relapse/Refractory AML
23 Oct 2023 //
PR NEWSWIRE
TC BioPharm to Present at the LD Micro Main Event XVI
27 Sep 2023 //
PR NEWSWIRE
TC BioPharm Announces Grant Funding in Collaboration with QMUL
05 Sep 2023 //
PR NEWSWIRE
TC BioPharm to Present at H.C. Wainwright 25th Annual Global Conference
29 Aug 2023 //
PR NEWSWIRE
TC BioPharm to Present at LD Micro Invitational XIII Conference on June 7, 2023
24 May 2023 //
PR NEWSWIRE
TC BioPharm Increases Allogeneic Car & Partnering Focus for Advancement TCB-008
26 Apr 2023 //
PR NEWSWIRE
TC BioPharm to Present at the Sequire Investor Summit in Puerto Rico
19 Apr 2023 //
GLOBENEWSWIRE
TC BioPharm Announces Closing of $5.5 Million Public Offering
30 Mar 2023 //
PR NEWSWIRE
TC BioPharm Announces Pricing of $5.5 Million Public Offering
28 Mar 2023 //
PR NEWSWIRE
TC Biopharm Announces Corporate Restructuring, Reduction in Overhead
22 Mar 2023 //
PR NEWSWIRE
TC BioPharm Restructures, Cuts Workforce up to 30%
22 Mar 2023 //
CONTRACT PHARMA
TC BioPharm Receives Extension from Nasdaq Hearings Panel to Regain Compliance With Listing Rule 5550(b)(2)
16 Mar 2023 //
PR NEWSWIRE
